TABLE 2.
Comparison of treatment duration and demographic and clinical characteristics of the three treatment cohorts in B‐MHC (N = 1392)
| Relative to COVID‐19 | Total | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Prior | Partially | Entirely | |||||||
| 1001 | 338 | 640 | 1979 | ||||||
| Initial sample size (N) | N | % | N | % | N | % | χ 2(2) | p | |
| Treatment dropouts | 108 | 10.8 | 55 | 16.3 | 97 | 15.2 | 10.03 | .007 | 1 < 2 = 3 |
| ROM response | 721 | 72.0 | 231 | 68.3 | 440 | 68.8 | 2.79 | .25 | 1 = 2 = 3 |
| M | SD | M | SD | M | SD | F(2) | p | Post hoc | |
| Age | 36.6 | 13.0 | 37.4 | 14.0 | 37.0 | 13.6 | 0.35 | .71 | 1 = 2 = 3 |
| Pretest severity (OQ‐SD) | 53.4 | 15.4 | 51.2 | 14.1 | 51.6 | 15.0 | 2.84 | .06 | 1 = 2 = 3 |
| Functioning (GAF) | 57.1 | 6.0 | 57.2 | 6.2 | 57.6 | 5.7 | 0.71 | .49 | 1 = 2 = 3 |
| N | % | N | % | N | % | χ 2(2) | p | ||
| Female gender | 484 | 67.2 | 155 | 67.7 | 287 | 65.4 | 0.53 | .77 | 1 = 2 = 3 |
| Diagnosis | N | % | N | % | N | % | χ 2(12) | p | |
| Depression | 307 | 42.6 | 81 | 35.4 | 132 | 30.1 | 30.31 | .003 | 1 > 2 > 3 |
| Anxiety | 139 | 19.3 | 58 | 25.3 | 92 | 21.0 | 2 > 3 > 1 | ||
| PTSD | 77 | 10.7 | 32 | 14.0 | 64 | 14.6 | |||
| Adjustment disorder | 59 | 8.2 | 15 | 6.6 | 54 | 12.3 | |||
| Pers disorder | 9 | 1.3 | 0 | 0.0 | 6 | 1.4 | |||
| Psychotic disorder | 62 | 8.6 | 23 | 10.0 | 44 | 10.0 | |||
| Other | 67 | 9.3 | 20 | 8.7 | 57 | 10.7 | |||
| Comorbidity | N | % | N | % | N | % | χ 2(6) | p | |
| No comorbidity | 406 | 56.4 | 133 | 58.1 | 267 | 60.8 | 2.81 | .59 | 1 = 2 = 3 |
| Axis 1 comorbidity | 296 | 41.1 | 91 | 39.7 | 165 | 37.6 | |||
| Axis 2 comorbidity | 18 | 2.5 | 5 | 2.2 | 7 | 1.6 | |||
| M | SD | M | SD | M | SD | F(2) | p | Post hoc | |
| Number of sessions | 15.0 | 7.8 | 18.5 | 7.0 | 15.8 | 8.7 | 16.73 | <.001 | 2 > 1, 2 > 3, 1 = 3 |
| Mean treatment duration | 124.6 | 73.5 | 200.8 | 73.3 | 141.5 | 70.7 | 95.67 | <.001 | 2 > 1, 2 > 3, 3 > 1 |